Genetic Variants of Annexin A2 and Cryptogenic Stroke
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- genetic variants of ANXA2
研究概览
简要总结
Stroke is the third most common cause of death in developed countries. Various mechanisms of ischemic stroke exist. However, in young population, in a third of cases, the cause of a stroke cannot be determined despite an extensive evaluation. Many studies have highlighted the link between stroke and fibrinolysis. Genetic variants of tPA and PAI-1 genes have been suggested to be the risk factors for stroke.
ANXA2 plays a pivotal role in plasmin generation and fibrinolysis. Several studies showed the role of ANXA2 and S100A10 subunits in regulation of fibrinolysis in vivo. Recently, the efficacy of recombinant ANXA2 for fibrinolytic therapy in a rat embolic stroke has been demonstrated. Some single nucleotide polymorphisms in ANXA2 gene could be associated with increased risk of stroke in sickle cell disease.
Therefore, these data invite us to test hypothesis that genetic variants of ANXA2 gene could be associated with ischemic stroke.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Completed ischemic stroke defined as a rapidly developing focal neurologic deficit with no apparent cause other than a vascular origin that persisted beyond 24 hours in surviving patients
- •Age from 18 years old
排除标准
- •Transient ischemic attack
- •Pregnancy
研究组 & 干预措施
control subjects
control subjects
干预措施: blood withdrawal (Biological)
cryptogenic stroke
cryptogenic stroke
干预措施: blood withdrawal (Biological)
ischemic stroke
ischemic stroke
干预措施: blood withdrawal (Biological)
结局指标
主要结局
genetic variants of ANXA2
时间窗: day 1
genetic variants of S100A10
时间窗: day 1
次要结局
- concentration of S100A10 directed against ANXA2(day 1)
- blood ANXA2 concentration(day 1)
- blood S100A10 concentration(day 1)
- concentration of Autoantibodies directed against ANXA2(day 1)